CorMedix Inc. (NasdaqGM: CRMD)
Health Care · Pharmaceuticals · US
$8.20
-0.36% today · -39.5% 1Y
CorMedix Inc. (NasdaqGM: CRMD) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $639.14M and employs 191 people.
Over the last twelve months the share price has lost 39.5%, trading between 6.13 and 14.96.
Tweenvest scores CorMedix Inc. across four factors: quality 56/100, value 46/100. Its strongest factor is quality.
CRMD price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $639.14M
- Revenue (TTM)
- $462.25M
- P/E
- 3.94
- EPS
- 2.08
- Dividend yield
- —
- Beta (5Y)
- 1.50
- 52-week high
- $14.96
- 52-week low
- $6.13
- Avg volume (3M)
- —
- Shares outstanding
- 77.94M
- Employees
- 191
- Next earnings
- —
About CorMedix Inc.
CorMedix Inc. is a biopharmaceutical company engaged in the development and commercialization of medical treatments for the prevention and care of infectious and inflammatory conditions, serving markets both in the United States and internationally. Its leading product candidate, DefenCath/Neutrolin, represents a novel anti-infective solution. This treatment aims to diminish and avert catheter-related infections and blood clots in patients who utilize central venous catheters for medical procedures such as hemodialysis, total parenteral nutrition, and oncology care. Incorporated in 2006, the company initially operated as Picton Holding Company, Inc. until officially adopting the name CorMedix Inc. in January 2007. Its corporate headquarters are located in Berkeley Heights, New Jersey.
- ISIN
- US21900C3088
- Founded
- 2006
- Listed since
- May 13, 2010
- Exchange
- Nasdaq Global Market
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.12T | $1,255.40 | +0.88% |
| Johnson & JohnsonNYSE: JNJ | $651.25B | $270.24 | +1.07% |
| Merck & Co., Inc.NYSE: MRK | $376.37B | $152.55 | +2.39% |
| Roche Holding AGSWX: ROP | $373.91B | CHF375.60 | +1.02% |
| Novartis AGSWX: NOVN | $302.17B | CHF127.42 | +0.85% |
| AstraZeneca PLCLSE: AZN | $258.76B | £122.40 | +1.26% |
| Novo Nordisk A/SCPSE: NOVO B | $207.84B | Dkr300.85 | +1.59% |
| Pfizer Inc.NYSE: PFE | $159.99B | $28.07 | +1.01% |
Figures last refreshed Aug 18, 2026.